The future of male contraception is on the horizon.

Over 17 million men are searching for new male contraceptive methods outside of what is currently available with vasectomy and condoms. Just as women have options with birth control pills or IUDs, men need options for themselves that are safe, long-acting, non-hormonal, and fully reversible on-demand.

Beginning in 2022, NEXT Life Sciences, took over the development of Vasalgel® from the Parsemus Foundation, bringing together some of the world’s most accomplished vasectomists, hydrogel experts, and contraceptive leaders to unite behind the vision of making this male contraceptive technology finally a tangible option in the market.

Plan A™ expands upon decades of research and clinical experience in the development of both RISUG and Vasalgel® technologies by also pioneering a new, minimally invasive delivery method designed to allow a provider to confirm with greater accuracy that Vasalgel® is properly positioned within the vas deferens to act as a contraceptive.

As we near our goal for Plan A™ clinical trials in 2024, we invite you to join this movement by staying updated on an exclusive newsletter list giving you company updates on the progress of Vasalgel® and Plan A™ as they progress toward marketing authorization.